Desflurane – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

Desflurane is the fully fluorinated successor to isoflurane and produces the fastest induction and emergence of any clinical volatile anesthetic, courtesy of the lowest blood-gas partition coefficient in the class (0.42). Approved in 1992 (Suprane). The high vapor pressure (it boils near room temperature) requires a special heated, pressurized vaporizer rather than the standard variable-bypass design. Hepatic metabolism is essentially negligible (under 0.02 percent), eliminating the fluoride and trifluoroacetylation concerns of older agents. The downsides: it irritates airways too much for inhalational induction, it triggers transient sympathetic surges with rapid concentration changes, and it has the highest global warming potential of the class (GWP100 around 2540, versus 130 for sevoflurane). Several health systems have restricted its use on environmental grounds. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

40/100

Mature clinical volatile with unmatched emergence kinetics, actively being retired for environmental reasons

Honestly, desflurane occupies a strange spot in a research library. It’s a 1992 FDA approval with the lowest blood-gas partition coefficient in the clinical volatile class, at 0.42, and that single number is genuinely the compound’s most interesting fact. Emergence times are faster than sevoflurane by a meaningful margin in long procedures, and that pharmacokinetic property has real investigational value for anyone studying recovery, post-operative cognitive dysfunction, or the kinetics of consciousness return. Those are legitimate research questions. The problem is that desflurane itself isn’t the probe you’d reach for to answer them.

The mechanism of action is the standard halogenated ether playbook: positive allosteric modulation at GABA-A, K2P channel activation, glycine receptor enhancement, NMDA modulation. Ross Terrell synthesized it at Anaquest looking for a less metabolized successor to isoflurane, and he got exactly that. Hepatic metabolism is below 0.02 percent of the absorbed dose, the lowest in the class, which was the original pharmacological appeal. But thats not a novel mechanism story. Thats a pharmacokinetic engineering win from four decades ago, and the research community extracted most of what it can from that angle a long time ago. A MAC of 6.0 percent in oxygen, the highest in the class, tells you roughly where the potency sits: real but unremarkable relative to sevoflurane’s 2.05 at similar endpoints.

The differentiation case rests almost entirely on emergence speed, and that case is eroding. Environmental restrictions are real and accelerating. The global warming potential of desflurane (GWP100 approximately 2540) is roughly 20 times that of sevoflurane and five times that of isoflurane. NHS England banned it in 2021. Major US academic health systems, including UCSF and Massachusetts General, have moved to sevoflurane-dominant protocols. When the compound is being actively removed from operating rooms, its utility as a clinical research tool contracts in parallel. You cant easily run a trial on a molecule your institution is phasing out.

Where desflurane retains genuine bench value is in controlled preclinical inhalational pharmacology work where rapid wash-in and wash-out are the specific variable under study. Rodent EEG work measuring anesthetic state signatures, or precise concentration-response experiments requiring fast kinetics, genuinely benefit from the 0.42 partition coefficient in ways sevoflurane can’t exactly replicate. The Tec 6-style heated pressurized vaporizer setup is a barrier, but for labs already equipped for inhalational work, theres a real niche here. Its just narrow.

We think the honest picture is a compound with a strong clinical track record, genuinely excellent pharmacokinetic properties for its original purpose, and almost no frontier research interest remaining. Evidence quality is high because thirty years of clinical use generates a lot of data. Novelty is essentially zero. For a bench scientist looking for compounds that illuminate new biology or address a question that cant be answered another way, desflurane isn’t where the signal is right now.

Novelty: 18
Mechanism promise: 20
In-category differentiation: 42
Evidence quality: 72
Translational signal: 68
Research bench value: 30

Rationale Desflurane’s pharmacokinetic edge is real and clinically documented, but the mechanism is entirely standard halogenated ether pharmacology with no novel angle, and institutional restrictions driven by a GWP100 of ~2540 are contracting its research footprint fast. High evidence quality and translational confirmation lift the score; near-zero novelty and shrinking bench utility hold it to the low forties.

Halogenated ether volatile general anesthetic

The fully fluorinated successor to isoflurane with the lowest blood-gas coefficient of any clinical volatile, enabling the fastest induction and emergence in the class.

Abstract

Desflurane (1,2,2,2-tetrafluoroethyl difluoromethyl ether; CAS 57041-67-5; molecular formula C3H2F6O; molecular weight 168.04) is a fully fluorinated methyl ethyl ether developed by Ross Terrell at Anaquest in the 1980s and approved by the FDA in 1992 (Suprane). The minimum alveolar concentration (MAC) at age 40 is 6.0 percent in oxygen, the highest of the clinical volatile anesthetics; the blood-gas partition coefficient is 0.42, the lowest in the class, producing the fastest induction and emergence kinetics among approved inhalational agents. The high vapor pressure (664 mmHg at 20 degrees Celsius, near the boiling point of 23 degrees Celsius) requires a heated, pressurized vaporizer (Tec 6 or equivalent) rather than the variable-bypass design used for isoflurane and sevoflurane. Mechanism is the standard halogenated ether profile: GABA-A positive allosteric modulation, K2P channel activation, glycine and NMDA modulation. Hepatic metabolism is minimal (less than 0.02 percent of an absorbed dose), the lowest among inhalational anesthetics, virtually eliminating fluoride-related nephrotoxicity and trifluoroacetylated hepatotoxicity. The principal clinical limitations are airway irritation that precludes inhalational induction (coughing, breath-holding, laryngospasm at concentrations above 6 percent in non-anesthetized patients) and sympathetic stimulation with rapid concentration increases producing transient tachycardia and hypertension. The high MAC and high vapor pressure make desflurane the most expensive volatile per case at typical fresh gas flows, though low-flow techniques mitigate cost. Environmental concerns about high global warming potential (GWP100 approximately 2540 versus 130 for sevoflurane and 510 for isoflurane) have driven institutional restrictions on desflurane use in several health systems.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1303Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.